KENGREXAL, (cangrelor), platelet aggregation inhibitor for injection

CARDIOLOGY - New medicinal product

Opinions on drugs - Posted on Sep 09 2016

Inclusion

KENGREXAL has Marketing Authorisation in combination with acetylsalicylic acid (ASA) for the reduction of thrombotic cardiovascular events in adult patients with coronary artery disease undergoing percutaneous coronary intervention who have not received oral P2Y₁₂ receptor inhibitors before this procedure and in whom the oral route for such treatment is not feasible or desirable.
It is administered intravenously, unlike the three comparators: clopidogrel, prasugrel and ticagrelor.
The cangrelor/clopidogrel/aspirin strategy has demonstrated its superiority relative to the aspirin/clopidogrel strategy on reducing ischemic event risk at 48 hours. The modest benefit observed mainly relies on the reduction of stent thrombosis risk, with no reduction in mortality. This benefit is nevertheless accompanied by an increased bleeding risk.
KENGREXAL is restricted to use in patients who need to undergo emergency angioplasty and who cannot swallow (intubated or sedated patients, in a context like cardiac arrest or cardiogenic shock) or in whom digestive absorption is greatly impaired.

Low

no clinical added value

Therapeutic use

Évaluation des médicaments

All our publications

My account